Specificity and polyreactivity of the antibody response during natural HIV-1 infection
- Published: 01 Jan 2006
- Country: Canada
- HANOI MEDICAL UNIVERSITY
- Shanxi Medical University China (People's Republic of)
- Simon Fraser University Canada
Introduction ...............................................................................................5..1..
Materials and methods ...............................................................................5..3. Reagents ...............................................................................................5..3... Antibody affinity purification - Trial 1 .....................................................54 Antibody affinity purification - Trial 2 ...................................................5..5 Direct ELISA for characterizing purified IgG binding to specific peptide ....................................................................................................5..6. Neutralization assay ...............................................................................5..7.
Discussion ...................................................................................................9..2 Figure 4-2: Regression of ELISA signal from 10 nM MAb CL 15 on net charge of synthetic peptides.................................................................................8..4..
Figure 4-3: Neutralization of pseudotyped HIV-I HxB2 by MAbs CL 15. 4E 10 and 15E......................................................................................................... 87 Figure 4-4: Figure 4-5: Anti-CL Abs as a marker for autoreactivity during HIV-1 infection...........88 Cardiolipin reactivity in sera (1 in 50 dilution)...........................................9.0 Table 2-1: Table of HIV- 1 MN Env peptides obtained from the NIH AIDS Research & Reference Reagent Program.....................................................30 Table 3-1: Summary of IC50 in neutralization assay with bNt serum #6. Merck serum (negative control)...........................................................................7..4.
Table 3-2: Comparison of Two Affinity Purification Systems, Sulfolink Agrose Gel and SA Beads.......................................................................................7.5 Table 4-1: HIV-1 MN Env (15-mer) peptides obtained from the NIH AIDS Research & Reference Reagent Program....................................................8.5 Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M. and Berger, E. A. (1996). "Cc Ckr5: A Rantes, Mip-1alpha, Mip-lbeta Receptor as a Fusion Cofactor for Macrophage-Tropic HIV- 1." Science 272(5270): 1955-8.
Ariyoshi, K., Harwood, E., Chiengsong-Popov, R. and Weber, J. (1992). "Is Clearance of HIV-1 Viraemia at Seroconversion Mediated by Neutralising Antibodies?" Lancet 340(8830): 1257-8.
Baba, T. W., Liska, V., Hofrnann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A., Posner, M. R., Katinger, H., Stiegler, G., Bernacky, B. J., Rizvi, T. A., Schmidt, R., Hill, L. R., Keeling, M. E., Lu, Y., Wright, J. E., Chou, T. C. and Ruprecht, R. M. (2000). "Human Neutralizing Monoclonal Antibodies of the IgG 1 Subtype Protect against Mucosal Simian-Human Immunodeficiency Virus Infection." Nat Med 6(2): 200-6.
Bahr, S.L. M.Sc. Thesis. Peptide Markers for the HIV-1 Neutralizing Antibo&, 4ElO. Simon Fraser University, Burnaby, BC, Canada. (2004).
Barbato, G., Bianchi, E., Ingallinella, P., Hurni, W. H., Miller, M. D., Ciliberto, G., Cortese, R., Bazzo, R., Shiver, J. W. and Pessi, A. (2003). "Structural Analysis of the Epitope of the Anti-HIV Antibody 2F5 Sheds Light into Its Mechanism of Neutralization and HIV Fusion." J Mol Biol330(5): 1101- 15.
Belshe, R. B., Gorse, G. J., Mulligan, M. J., Evans, T. G., Keefer, M. C., Excler, J. L., Duliege, A. M., Tartaglia, J., Cox, W. I., McNamara, J., Hwang, K. L., Bradney, A., Montefiori, D. and Weinhold, K. J. (1998). "Induction of Immune Responses to HIV- 1 by Canarypox Virus (ALVAC) HIV- 1 and gp 120 SF-2 Recombinant Vaccines in Uninfected Volunteers. NIAID AIDS Vaccine Evaluation Group." AIDS 12(18): 2407- 15.
Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W. and Montagnier, L. (1983). "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)." Science 220(4599): 868-71.
Berkower, I., Murphy, D., Smith, C. C. and Smith, G. E. (1991). "A Predominant GroupSpecific Neutralizing Epitope of Human Immunodeficiency Virus Type 1 Maps to Residues 342 to 511 of the Envelope Glycoprotein gp120." J Virol 65(11): 5983- 90.
Binley, J. M., Jin, X., Huang, Y., Zhang, L., Cao, Y., Ho, D. D. and Moore, J. P. (1998). "Persistent Antibody Responses but Declining Cytotoxic T-Lymphocyte Binley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S., Katinger, H., Petropoulos, C. J. and Burton, D. R. (2004). "Comprehensive Cross-Clade Neutralization Analysis of a Panel of AntiHuman Immunodeficiency Virus Type 1 Monoclonal Antibodies." J Virol78(23): 13232-52.
Bjomdal, A., Deng, H., Jansson, M., Fiore, J. R., Colognesi, C., Karlsson, A., Albert, J., Scarlatti, G., Littman, D. R. and Fenyo, E. M. (1997). "Coreceptor Usage of Primary Human Immunodeficiency Virus Type 1 Isolates Varies According to Biological Phenotype." J Virol71(10): 7478-87.
Bradney, A. P., Scheer, S., Crawford, J. M., Buchbinder, S. P. and Montefiori, D. C. (1999). "Neutralization Escape in Human Immunodeficiency Virus Type 1- Infected Long-Term Nonprogressors." J Infect Dis 179(5): 1264-1267.
Powered by OpenAIRE Research Graph